View all veterinary jobs
VetSurgeon.org publishes a curated feed of veterinary news for practising veterinary surgeons, with a primary focus on the UK profession.
We select stories based on their practical relevance, clinical interest, or professional significance — filtering out noise so busy vets can stay informed quickly.
Our coverage includes:
We report across all areas of practice, including companion animal, farm, equine and exotic species.
Our editorial approach is deliberately selective and concise. We prioritise clarity and relevance over volume, aiming to make each story worth your time.
You can follow VetSurgeon News by subscribing to the daily, weekly or monthly email digest, or via our channels on Facebook and LinkedIn.
Euthasol vet is presented as a clear blue liquid, licensed for intravenous, intracardial and intraperitoneal usage. A dose of 140 mg/kg (equivalent to 0.35 ml/kg) is considered sufficient for all licensed routes of administration.
Euthasol vet comes in vials of 100ml and has a 28 day broached shelf life.
Dechra Brand Manager Claire Morgan said: "Choosing the correct product for euthanasia is vital for veterinary professionals and Euthasol vet offers a highly effective solution.
"The intravenous route of administration should be the route of choice. Where intravenous administration is impossible, the product may be administered via the intracardiac route in all named species.
"Euthasol's versatility in terms of the range of species in which it is licensed for use, coupled with its 400 mg/ml concentration, is set to make it a popular choice in practice."
For more information, visit www.dechra.co.uk
The Group has trained almost 100 of its staff as 'mental health first aiders'.
Michelle O’Connor, the Linnaeus Group’s people and culture director (pictured right), said: "Veterinarians are three to four times more likely to die by suicide than workers from any other industry.
"Because of this alarming statistic, we have put wellbeing at the very forefront of our strategy and have so far trained nearly 100 mental health first aiders within the group.
The Linnaeus volunteers, who are taken from both office and clinical roles, have all attended a training course run by Mental Health First Aid England (MHFA) to acquire the skills to support their own and others’ wellbeing.
The MHFA course trains people to identify the signs of mental ill health, to break down the stigma and barriers surrounding mental health and listen to colleagues in a non-judgemental way, and to help direct those suffering from issues to the support and guidance that’s available.
Michelle added: "We realise training on how to spot signs of a crisis and become a mental health first aider alone does not address the prevailing stigma around mental health in the workplace.
"So, in addition, we are developing a culture where support and conversations about mental health are normalised, so that colleagues feel able to reach out for the important support they need."
According to Mandadeals.co.uk, CVS has agreed to buy Veterinary Enterprise and Trading, including it's 27 surgeries in the South East of England which operate under the Pet Doctors brand and Greendale, its diagnostic and laboratory business, for £12.2M.
The book guides the reader through the evolutionary background of dogs and cats and explains how inherited diseases and deformities associated with certain breeds can cause breathing problems, heart disease, skin problems and back problems.
The book concludes with practical advice to help owners buy a healthy puppy or kitten and to avoid the risk of supporting puppy farms.
Emma said: "I’ve been campaigning on this issue for twenty years and, if anything the conformational issues and inherited disease problems in dogs and cats, are getting worse with some breeders striving for ever more extreme body shapes.
"Selecting a pet with inherited defects can cost thousands in vet bills and cause anguish for family members. It also creates a relinquishment problem for animal shelters as they have to take in abandoned pets with health problems.
"While awareness is certainly increasing, too often prospective pet owners are still unaware of the health implications of the pet they are buying and it is difficult for my veterinary colleagues to criticise the choice of a client’s puppy or kitten once it has been bought. All too often though they are left to pick up the pieces."
Emma added: "Education is the key. It is vital that prospective owners understand why different body shapes could be detrimental to health and how far removed from nature some of our breeds now are. If we can encourage them to stop choosing the quirky extremes in some breeds, demand for them will soon fall. My message is simple – we should all prioritise health and temperament way above what animals look like.
"I hope that responsible prospective pet owners will find Picking a Pedigree? an enlightening read and that it will inform their choice of a new family member. I also hope that it will be a useful resource for vets and nurses to be able to recommend to reinforce their pre-purchase advice."
The charity launched the 'Cat Friendly Clinic' accreditation scheme in 2012, in order to raise standards and reduce the stress experienced by cats (and consequently their owners) when visiting clinics.
In order to be accredited as a Cat Friendly Clinic, a clinic must not only meet high standards of cat care in terms of facilities and equipment, but staff must also demonstrate an understanding of the needs and behaviour of cats and put in place measures to ensure that visits to the clinic are more cat-friendly.
In the six years since its inception, the scheme has become a well-recognised standard in feline veterinary care, with accredited clinics all over the world.
The Classic Animal Hospital in South Korea (wow, see the architects' photos here), was founded in September 2017 and consists of three vets, eight nurses and three receptionists. Open 24 hours a day, 365 days a year, the clinic's goal is to "provide outstanding veterinary care using the most advanced medical techniques and equipment in an environment that is both comfortable and welcoming for owners and their loved companions’. Currently, about 30% of the clinic’s clients are cats, and this percentage is continuing to grow.
Park Sungwon, owner of the clinic and Chief of Surgery, said: "Since more and more Koreans are having cats as their companion animals, there is growing interest in the Cat Friendly Clinic programme. So many veterinarians who have just started or want to start their own clinic share information about becoming a Cat Friendly Clinic. I also found out about the Cat Friendly Clinic scheme on the vet internet community. When I decided to open my clinic, I planned to become a Cat Friendly Clinic. So I took ISFM’s requirements into consideration when I designed my clinic."
When asked what cat owners think of the clinic’s Cat Friendly status, Park said: "They are very satisfied with our separated, quiet, cat-only waiting area and large hospitalisation facilities. They think that their cats definitely feel more comfortable at my clinic than they feel at other clinics in my town."
Sarah Endersby, International Cat Care’s Veterinary Development Manager, said: "We are delighted to have accredited the 1000th Cat Friendly Clinic. It is fabulous to know that many veterinary clinics around the world are thinking about how they can make feline visits less stressful, benefitting not only the cats themselves, but their owners and the veterinary team. We have many clinics looking to become a Cat Friendly Clinic, so the community is growing quickly - hopefully we will be welcoming the 2000th clinic in the not too distant future!"
To find out more about the Cat Friendly Clinic scheme, visit catfriendlyclinic.org.
The scheme is supported by six official partners: Boehringer Ingelheim, Ceva, Elanco, Idexx, Merial and Royal Canin.
Urging vets to 'get off their backsides and respond to a VMD consultation' on the introduction of a new POM-EA category (Vet Times, 19th October) is premature.
Contrary to the report, the VMD has not yet launched a formal consultation.
Jo Cawthorne from the VMD said: "In fact, we've only launched an informal consultation on a concept note amongst a small group of key stakeholders from the RCVS, BVA, RPSGB, AMTRA, AHDA and NOAH, in order to decide whether this is a viable idea and merits a formal consultation."
She added: "There is no need for vets to respond to a consultation which doesn't yet exist. If there is a formal consultation, it will be announced formally on our website and everyone will be given the opportunity to respond."
Royal Canin has announced that it will be launching Multifunction, a new range of veterinary diets designed for cats and dogs experiencing - or at risk of - multiple health conditions.
According to the company, 35% of cats and dogs meet this description1 and it can be difficult for veterinary surgeons and nurses to recommend a diet which meets all their needs when one diet can't address multiple nutritional priorities.
Officially being launched at BSAVA, Multifunction diets are designed to provide an option for the nutritional management of cats and dogs with more than one condition, thereby eliminating the need to decide which of two conditions take precedence when developing a nutritional assessment for patients.
The company says that the new diets have been developed by combining existing Veterinary Diet formulae. The range includes:
Marianne Lomberg, Veterinary Marketing Manager said: "As a company, one of the things we are proud of is looking at the pet as a whole, rather than just a clinical condition on legs. For this reason we combine the features of our standard veterinary diets to provide support for other issues that a pet may develop. For example, our Urinary Moderate Calorie diet is lower in calories than standard diets in order to help prevent weight gain in animals predisposed to obesity as a result of living indoors or being neutered. However, until now, we have not been able to provide vets with a diet for a pet that has already been diagnosed with two equally serious concurrent conditions, such as lower urinary tract disease and obesity. Our new Multifunction diets do just this.
"Pets suffering from more than one condition also generally require more regular veterinary care, too, and a unique new ordering system for these diets helps facilitate ongoing contact between the pet owner and their veterinary practice every time they order a new bag of food. More information about the diets and the ordering system will be available on the ROYAL CANIN, stand: 611."
Multifunction will only be available through veterinary practices and all bags will be personalised, including the practice logo and patient name. Further information on how to sign up to the product programme will be available at the show stand.
For more information, visit: http://new.vetportal.royalcanin.co.uk/products/multifunction-2/
Reference
Mark, who graduated from Cambridge University in 1997, has a broad interest in internal medicine but particularly enjoys the challenges posed by gastrointestinal, endocrine, haematology and renal medicine.
He has a PhD in Neuroscience at the University of Cambridge and after completing his PhD he took a residency in Small Animal Medicine at Cambridge, followed by four years in a private specialist practice in the south of England.
Mark was then appointed Clinical Associate Professor in Small Animal Internal Medicine at the Nottingham Veterinary School, where he was responsible for running the final year medicine rotation along with lecturing to all years of the veterinary course.
He was also in charge of the school’s small animal intern and residency programmes in addition to supervising both undergraduate and post-graduate research students.
Mark has also been involved in national and international investigations into canine breed-related diseases such as canine cancer, canine and feline haematology, canine endocrine disease and the development of novel non-invasive biomarkers to help diagnose both simple and complex medical diseases.
Outside work, Mark is a seven-guitar-owning-musician, a race-winning cyclist and a keen runner with a personal best of one hour twenty five minutes for a half marathon. What a relief for the rest of us mere mortals to hear there's something he's rubbish at: he says he swims 'like a brick'.
Mark said: "I’m excited to be joining the outstanding team at Willows who deliver such exceptional care to pets and their owners and such an outstanding service to the referring veterinary surgeons.
"It is a wonderful opportunity for me and I’m really looking forward to making my own contribution to their continued success."
CEVA Animal Health is giving away a key ring torch with every three bottles of Rehydion gel®, its product for scouring calves.CEVA says the deal is to highlight the fact that Rehydion gel® is currently the only oral rehydration treatment that can be added to milk, with guaranteed milk clotting. According to the company, Rehydion gel® has faster, guaranteed milk clotting and helps to maintain a low abomasal pH. Its high palatability and efficient dilution in milk allows weight gain to continue, even in cases of severe scour. It also has a high Strong Ion Difference (SID) which effectively suppresses acidosis. Rehydion gel® is fast to mix by simply shaking the hand-held bottle. Rehydion gel's® consistency means that precise doses of alkalinising agents and electrolytes can be squeeze-delivered with ease. In beef systems the product is time-saving, convenient and minimises stress as it can be given neat, meaning there is need for the calf to be separated from its dam. One bottle provides enough for eight, two-litre calf feeds or 160 feeds for lambs. The distinctive yellow top also acts as a handy measuring cap.
Further information and product literature is available from Martin Gough on 01494 781510.
Robexera is a COX2 NSAID formulation which delivers anti-inflammatory pain relief with a once-a-day dosing regime2,3,4.
The product is presented as a flavoured chewable tablet for easier administration by pet owners.
For simplicity when dispensing, it comes in four strengths with colour coded boxes, perforated blisters and a set of PIL sheets that convert to prescribing envelopes in each pack.
Charlotte Read, Krka’s UK Key Account Manager, said: “Delivering reliable, cost-effective perioperative pain relief for soft tissue surgery is an everyday concern for veterinary practices, while OA is the most common cause of chronic pain in dogs5.
"This is why we’re particularly pleased to announce the first generic robenacoxib, Robexera.
“Bioequivalent to the originator product6, Robexera provides fast-acting and targeted pain relief, giving enhanced value to veterinary practices and enabling them to offer their clients improved affordability, particularly for those whose animals are on long term pain-management programmes or have other health issues.”
Viktor Kozjan, General Manager Krka UK, added: “The launch of Robexera is further confirmation of Krka’s commitment to develop solutions that are tried and trusted but also flexible and affordable for our customers and their clients.”
Robexera is now available to order from all national UK veterinary wholesalers.
References
The debate, which was described as 'robust but good-humoured', was moderated by BEVA past-President Madeleine Campbell, sole partner at Hobgoblins Equine Reproduction Centre.
Keith Chandler, former BEVA President and member of the acquisitions team at Independent Vet Care and Karl Holliman, partner and director at Cliffe Veterinary group and past chairman of XL Equine, argued for corporatisation.
Their supporting witnesses were Lesley Barwise Munro of AlNorthumbria vets which was sold to CVS in 2015 and Julian Samuelson a former managing partner of Bell Equine, which was sold to CVS earlier this year.
In the opposing corner were Andrew Harrison, a partner at Three Counties Equine Hospital and Tim Greet, who recently retired as an equine partner at Rossdales.
Their supporting witnesses were Louise Radford MRCVS, who now works in the pharmaceutical industry and Nenad Zillic, partner at the Barn Equine Surgery.
As the moderator called 'seconds out', opinion was relatively evenly divided, with 44% of the audience agreeing with the motion and 56% disagreeing.
The pro corporatisation team advocated that obvious commercial and business advantages, together with the scale and diversity of a corporate, can give vets greater potential for a more flexible career path and advancement within the industry, and a more sustainable working career in equine practice.
Karl Holliman pointed out that corporates enable greater purchasing power, better health and safety resources, improved career structure and the freedom for employed vets to focus on clinical expertise rather than becoming bogged down with practice management.
Keith Chandler went on to argue that selling to a corporate is a solution to the problem of succession planning. In a climate of unwillingness for younger vets to buy in to practice, selling allows partners to realise the value they've built up and release that equity to do something else.
This is all very well, said Tim Greet, on the anti corporatisation panel, but the good reputation the profession currently enjoys is based on service to clients and above all the animals in our care. Clinical rather than commercial elements drive practice and partners are light on their feet and can respond quickly to decisions without referring to "a ponderous corporate hierarchy".
Tim also argued that clients like continuity and the quickest way to lose them would be to send in different vets. A bespoke approach to client care was needed rather than hard targeting.
Andrew Harrison went on to suggest that the only vets who really benefit from selling out are those who have one eye on retirement. Younger partners may be able to pay off the loan they took out to buy into practice in the first place but are then likely to take a considerable drop in salary and be given a middle management job, moving from the "pilot seat into the passenger seat." He argued that young vets cannot afford to buy into practices because the industry is being "fuelled by the corporates who are falling over themselves competing to buy equine practices and squeezing out our fellow professionals."
Pro corporatisation witness Julian Samuelson maintained that since Bell Equine has been sold to CVS there has been no change to client service, no restrictions on clinical performance and that no targets have been imposed to achieve set revenues.
Anti-corporatisation witness Louise Radford made the point that big corporates could exert pressure on pharmaceutical companies to drive down prices, which would reduce their capacity to invest in research and development trials and CPD, to the ultimate detriment of the veterinary industry.
The session closed with 72% of the audience disagreeing with the motion Corporatisation is inevitable and will benefit vets and their clients.
BEVA President Jon Pycock said: "Whether we like it or not corporatisation of equine practices is on the rise. But it shouldn’t mean that the future isn’t going to be viable for independents too as there is a role for both to co-exist. Importantly, this should mean that vets and their clients will both continue to have choices."
55 veterinary surgeons took part in the survey, which also found that only 37% of clinicians use FNA and cytology when investigating a suspected lipoma.
According to the survey, the biggest barriers to further investigations of lumps and bumps were cost (50%), short consult time (23%) and confidence in results (20%).
HT Vista, which earlier this year launched a cancer screening device for dogs which uses heat diffusion technology and AI to differentiate between benign skin masses and other tumours, is urging more practising vets to use an accurate screening process for early detection of malignant masses.
Dr. Gillian Dank, Board Certified Oncologist and Chief Veterinary Officer at HTVet, said: “There is no way to know that a mass is a lipoma based on palpation alone.
"The fact that a mass is subcutaneous, soft and circumscribed is not exclusive to lipoma and it could be a number of things including a mast cell tumour or sarcoma.
"On average a veterinary practice sees over 500 dermal and subcutaneous masses each year.
"We know anecdotally, and surveys like this confirm, that not every mass is aspirated – and that is why there is need for the HT Vista screening device.
"Every mass that comes in should be properly examined.”
“It’s interesting to see that the more experienced a clinician is, the less confident they are in diagnosing from palpation and this shows us that with experience we understand that our hands are not enough.”
Liron Levy-Hirsch, Managing Director of HT Vista, said: “The survey showed that vets are conscious of the cost to clients, and also feel pressured due to time.
"We have developed the HT Vista to complement FNA and cytology, and hope clinicians find it a useful tool.
"Firstly, it is quick and affordable to scan, and for those masses that are benign it removes the need for unnecessary FNA’s.
"Secondly, vets are often wary of cost, however if a mass is scanned and the results indicate that further investigation is needed, there is more rationale to spend the extra money to get the cytology results.
"Finally, the device can offer complete confidence that malignancies are not being missed, and if a mass is malignant a prompt treatment plan can be initiated.”
https://www.vetreport.net/wp-content/uploads/2023/08/Lump-and-Bump-Survey-2023FINAL.pdf
https://ht-vista.uk
To enter the competition, VetSurgeon members just needed to post a 'top tip' that could in any way make life easier, quicker, better or happier for a colleague.
Making use of the new feature on VetSurgeon.org where members can click a link marked 'thank you' to show their appreciation of something useful shared by someone else, VetSurgeon offered five £50 Amazon Vouchers for the most thanked tips shared before the end of November.
The winners are:
Mark Rowland for his tip that Mikki Muzzles make great anaesthesia masks for guinea pigs.
Emma Robinson for her solution to the problem of opening a new bottle "that has one of those annoying little metal caps".
Kate Richardson for her tip, which was to use an elastic band to 'tie' your et tubes in.
Julie Innes for her suggestion to use an elastic/ Velcro back support wrap from the Pound Shop when doing hip scores.
Gillian Mostyn for things you can do with a latex glove.
Bravecto Triuno is approved for the treatment of tick and flea infestations in dogs (Ctenocephalides felis, C. canis, Dermacentor reticulatus, Ixodes hexagonus, Ixodes ricinus, and Rhipicephalus sanguineus).
It is also approved for the treatment of infections with roundworms (adult stages of Toxocara canis and Toxascaris leonina) and hookworms (L4, immature adult (L5), and adult stages of Ancylostoma caninum and Uncinaria stenocephala), for the prevention of heartworm disease (caused by Dirofilaria immitis), and for the prevention of angiostrongylosis (by reduction of the level of infection with immature adult (L5) and adult stages of Angiostrongylus vasorum).
Victoria Miles, UK Companion Animal Director, MSD Animal Health, said: “With this latest formulation of Bravecto, MSD Animal Health is giving veterinarians and dog owners a greater range of convenient options for protecting their dog year-round from parasites, and all from the same trusted Bravecto portfolio.”
She added: “We see Bravecto Triuno as a great option for puppies that require a monthly wormer on top of protection against fleas and ticks.
"This also gives flexibility later on for the dog to remain with the Bravecto brand but be swapped onto a longer-duration flea and tick product with a wormer administered according to a veterinarian’s risk-based assessment.”
Bravecto Triuno is available as a flavoured chewable tablet indicated for dogs and puppies from 8 weeks of age and at least 1.27 Kg body weight and can be administered monthly to dogs at risk of infestation by multiple types of internal and external parasites.
It contains three anti-parasitic ingredients including fluralaner, which provides activity against ticks and fleas, moxidectin, which provides systemic activity against non-intestinal worms, and pyrantel, which provides activity against intestinal worms.
https://www.noahcompendium.co.uk/?id=-488423
The Sutton Bonington Campus, home of the University of Nottingham's School of Veterinary Medicine and Science, has raised £610 for Sport Relief with its annual Science Cake Competition.
There were thirty entries to the competition, in categories which included Animals & Agriculture, Food & Nutrition, Infection, 'Nerdy' Science, Plants, Crops & Environment, and Veterinary Medicine.
A special category this year was 'Cakes for Animals', which Emily Blight, an undergraduate vet student, organised for a panel of dogs to judge on tastiness.
The winner of the public vote was 'What came first, the chicken or the cake?' (pictured right), whilst the overall winner was Alex Burgess with ‘Dave’s Allotment’.
One of the judges, Dr Mike Jones said: "Choosing the winner was extremely hard. Every cake had its own specific merits be it the execution of the design, through to the novelty of ingredients and ideas or how they fitted into the categories." He added that he "was almost put off jelly beans for life - they will be forever associated with sheep back sides."
The cakes are all on display here.
Dr Russell, 64, who waived his right to attend the hearing, was convicted in 2023 of three offences: making indecent photographs of a child, possessing 2,280 prohibited images of a child and possessing 109 extreme pornographic images that included moving images that were grossly offensive.
After pleading guilty to making indecent photographs/pseudo-photographs of a child, possessing a prohibited image of a child, and possessing extreme pornographic image/images portraying sexual acts with an animal, Dr Russell was sentenced at Winchester Crown Court to a two-year community order, a 30-day Rehabilitation Activity Requirement, 150 hours of community service and a forfeiture and destruction order of Seagate Drive, Toshiba hard drive and Lenovo tablet.
In addition, he was required to register with the police for 5 years and made subject to a Sexual Harm Prevention Order for five years.
He was also required to pay prosecution costs of £425 and £60 victim surcharge.
Counsel for the College submitted to the Disciplinary Committee that the nature and circumstances of the offences rendered Dr Russell unfit to practise as a veterinary surgeon.
The Committee considered there to be several aggravating factors including, actual (albeit indirect) injury to an animal or child; the risk of harm to an animal or child; sexual misconduct; premeditated conduct; and, that the offences involved vulnerable children and animals.
Neil Slater, chairing the Committee and speaking on its behalf, said: “The Committee has reached the conclusion that Dr Russell’s behaviour is fundamentally incompatible with being a veterinary surgeon, namely grave offences of a sexual nature.
"Dr Russell’s behaviour was so serious that removal of professional status and the rights and privileges accorded to that status is considered to be the only means of protecting the wider public interest and of maintaining confidence in the profession.
“The Committee has not taken this decision lightly, and, lest it be misinterpreted, it has not taken it in order to satisfy any notional public demand for blame and punishment.
"It has taken the decision because, in its judgment, the reputation of the profession has to be at the forefront of its thinking and ultimately this is more important than the interests of Dr Russell.
"The decision is not simply based on the fact that these offences were of a sexual nature but because they were repeated over a significant period of time and at a time when Dr Russell must have known, on his own plea of guilty, that what he was doing was wrong.
"Further, the Committee can discern no evidence that Dr Russell has insight into the gravity of the offence he has committed.
"The Committee has therefore directed the Registrar to remove his name from the Register forthwith.”
Dr Russell has 28 days from being notified of his removal from the Register to lodge an appeal with Privy Council.
Skin diseases and palpable masses are a common presentation in guinea pigs brought for veterinary care2.
However, few studies have thus far looked at the prevalence of spontaneously arising diseases in pet guinea pigs.
"Lumpy bumpy guinea pigs: a retrospective study of 619 biopsy samples of externally palpable masses submitted from pet guinea pigs for histopathology" retrospectively analysed 619 biopsy samples submitted for histopathology from pet guinea pigs that had presented with externally palpable masses.
The purpose was to determine the most common tissue origins of these masses and the most frequent pathological diagnoses, together with signalment data for the most commonly diagnosed lesions.
Of the 619 samples submitted from 493 animals, 54 (8.7%) had arisen from the mammary glands3 and 15 (2.4%) from the thyroid glands, with the remaining 550 (88.9%) involving the skin and subcutis, muscle (n = 1), salivary glands (n = 4), lips (n = 2), ears (n = 4) and peripheral lymph nodes (n = 23).
Forty-seven (7.6%) of the masses were diagnosed as inflammatory in nature, including dermatitis, panniculitis, lymphadenitis, cheilitis, myositis, sialoadenitis, abscess and chronic inflammation with osseous metaplasia.
Non-neoplastic, non-inflammatory lesions accounted for a further 31 (5.0%), namely cysts, hamartomas, hyperplastic lesions, polyps, ectopic bone formation and salivary gland steatosis.
The remainder of the samples were neoplastic in nature (541; 87.4%), with 99 masses classified as epithelial in origin, 347 as mesenchymal, 23 as round cell, five as melanocytic and eight as unclassified malignant neoplasms.
Of these, mesenchymal neoplasms were further subdivided into benign (288) and malignant (59).
Lipomas were the most common neoplasm diagnosed, accounting for 286 of all samples submitted.
Of all 619 samples included in the study, the eight most commonly diagnosed lesions were lipoma (46.2%), trichofolliculoma (12.3%), sarcoma (of various subtypes: 9.5%), inflammation (all sites 7.6%), lymphoma / leukaemia (3.4%), mammary carcinoma (4%), mammary adenoma (3.2%) and thyroid carcinoma (1.5%).
Overall these eight diagnoses accounted for 87.7% of all submissions from the externally palpable masses from the pet guinea pigs submitted for histopathology.
Melanie said: “Guinea pigs are an increasingly popular household pet.
"Skin diseases, including palpable masses, are a common reason for veterinary presentation. But few studies have been published to date that provide information for clinicians about these conditions.
“This study illustrates the importance of neoplasms of the skin and subcutis in pet guinea pigs, with over 87% of the cases analysed having one of eight diagnoses.
"While most of these neoplasms are benign, a substantial minority are malignant and identifying those lesions is especially important in treatment planning.
"Clinicians dealing with pet guinea pigs should also be aware that some externally palpable masses may arise from the thyroid or mammary glands rather than the skin or subcutis, and that male guinea pigs may also develop mammary lesions.”
The paper has been selected as ‘Editor’s Choice’ by the Journal of Comparative Pathology and will be free to access until September on Lumpy, bumpy guinea pigs: a retrospective study of 619 biopsy samples of externally palpable masses submitted from pet guinea pigs for histopathology - ScienceDirect.
Dechra says that Dexacortone, which is presented as a flavoured double-divisible tablet, is approximately 25 times more potent than short-acting substances such as hydrocortisone.
Dechra Brand Manager Carol Morgan said: “Dexamethasone works to suppress the inflammatory response and should be combined with treatment of the underlying disease.”
The chewable tablets have been developed with a chicken flavour to encourage greater acceptance by animals and have Dechra’s double divisible SmartTab format to help accurate and flexible dosing.
Dexacortone is available in blister packs.
Carol added: “The dose and duration of treatment should be determined by the veterinarian based upon the desired effect and on the nature and severity of each individual case and our SmartTab format makes Dexacortone tablets easily divisible. The tablet portions have a six day shelf life that also reduces the wastage of medicine.”
For more information visit www.dechra.co.uk
After tense negotiations which stretched well into the night, Jenny Smith MRCVS has been confirmed this morning as the new face of VetSurgeon.org.
Jenny, who qualified earlier this year (congratulations), will appear in advertisements for the site in Veterinary Practice magazine, The London Vet Show Guide and Cattle Practice. She said: "I'm only too pleased to help promote VetSurgeon.org. It helped me understand what happens in the real world whilst I was at university, and I got my very first job as a veterinary surgeon through the contacts I made on the site."
Jenny is the third face of VetSurgeon, replacing Niall Taylor MRCVS, who has held the post since taking over from Gillian Mostyn MRCVS in December 2009. He said: "I'm ruined. Ruined, you hear. Without this contract, I'll probably have to go and open branches of Aldi on wet Saturday afternoons."
In fine tradition, Jenny is donating her £100 fee to the Northern Rose Boxer Rescue charity.
VetSurgeon member Alex Gough MRCVS, Head of Medicine Referrals at Bath Veterinary Referrals, has published his second historical thriller, Bandits of Rome, available for pre-order now in paperback (£7.99) or Kindle (£1.99) from Amazon.
The book picks up the story of Gaius Valerius Carbo as he leaves Rome with his family for the Italian countryside, only to be set upon by masked bandits.
Alex's first thriller, Watchmen of Rome, went to the top of the Amazon bestseller charts and has achieved reader reviews of an average 4.4 out of 5 stars.
Apparently the more people that pre-order the book before the 26th August, the higher it'll go up the charts. So if this sounds like it could be up your street, buy it today and you'll give a colleague a helping hand up the ladder at the same time.
Boehringer Ingelheim Vetmedica Ltd has announced that Metacam is now available for use in pigs as an oral suspension.
Metacam, which contains the non-steroidal anti-inflammatory drug (NSAID) meloxicam, is indicated for the treatment of non-infectious locomotor disorders to reduce inflammation and signs of lameness. It is also licensed for the treatment of mastitis-metritis-agalactia (MMA) syndrome in sows, when used alongside appropriate antibiotic therapy. MMA is a multifactorial condition that can threaten the health of the sow and the lives of her piglets due to a marked decrease or complete cessation in milk production.
Boehringer says treatment with Metacam15 mg/ml oral suspension helps control inflammation and pain associated with the condition, thereby helping to restore productivity and wellbeing in the sow and her offspring.
Metacam 15mg/ml oral suspension for pigs supplements the existing injectable formulation and has been introduced to its increase flexibility and ease of use, and to reduce the potential stress than can be caused when injecting newly-farrowed sows. The palatable suspension can be given mixed with a small quantity of feed or can be administered directly into the mouth.
The changes are designed to make the process more accessible and the College says most were proposed as a result of candidate feedback. They are:
The changes will come into effect from 1 January 2025, in time for the 2025 Stat Exam cohort.
Dr Linda Prescott-Clements, RCVS Director of Education, said: “We have been listening to the concerns of various stakeholders, including those who have undertaken the Stat Exam previously and veterinary employers, and we used this feedback to work with the Department for Environment, Food & Rural Affairs (Defra) to come up with a set of practical, deliverable changes that improve the experience of Stat Exam for all candidates, and hopefully alleviate some of the stress involved around timescales, opportunity and finance.
“These changes will make the exam more accessible, as it will allow candidates to have two attempts at the written papers within the same diet, which need to be passed before being allowed to proceed to the practical exam and it will also help improve accessibility to the exam from the perspective of candidate finances.
www.rcvs.org.uk/statutory-membership-exam
DogStem has been shown to be effective, reducing pain and lameness and improving mobility and quality of life for three months to over twelve months following a single injection1,2.
In a prospective, randomised, double-blinded, placebo-controlled trial of DogStem, results showed that2:
TVM highlights how DogStem simplifies the process and reduces the cost of using stem cell therapy in practice because unlike previous therapies, it does not require require a surgical harvesting procedure to be carried out under general anaesthetic.
Helen Harrison, DogStem Technical Vet and Product Manager said: "Osteoarthritis is one of the most common diseases seen in veterinary practices and is challenging to manage.
"Conventional medical treatments typically address the symptoms rather than the underlying pathological processes.
"At the same time, local treatment options that slow progression of osteoarthritis have been limited and surgical interventions aren’t always possible or may be unrewarding.
"We’re delighted to be able to offer vets DogStem®, a stem cell product with a strong evidence base across numerous mobility and quality of life parameters.’
DogStem can be ordered from NVS, or direct from: www.dogstem.co.uk
James qualified from Glasgow University in 2002 before joining Rosemullion Veterinary Practice, a mixed practice in Falmouth, Cornwall, of which he became a Director in 2008.
In 2014, Rosemullion separated its farm and small animal work, whereupon James became Clinical Director of the new farm practice, Coast2Coast Farm Vets.
In 2015, following the acquisition of Rosemullion and Coast2Coast by CVS, he was appointed to the group's Farm and Equine Clinical Advisory Committees. These Committees comprise clinical staff from across the Farm and Equine Divisions and make decisions on important issues, including purchasing, advice and information for its clinical teams and investments in the latest equipment and facilities.
James said: "I’ll be spending time each week travelling around the UK, Ireland and Holland to visit our farm practices and meet with colleagues within CVS and from the wider farming and veterinary industries.
"During my first six months, I’ll be focusing on developing frameworks and policies that will enable our practices to guide clients through difficult issues, such as antimicrobial and anthelmintic resistance and to help them succeed in the highly competitive marketplace for both prescription and non-prescription medicines.
"I will also be creating a bespoke farm New Graduate Programme for young vets which all our farm practices will be able to access.
"I see an exciting opportunity for CVS Farm to become a major force in the sector and am looking forward to working with my new colleagues to bring this about."
Ceva Animal Health has launched Amodip, described as the first ever cat-friendly amlodipine licensed for veterinary use for the treatment of hypertension in cats.
Amodip is a chicken-flavoured, two-way break chewable tablet; its 1.25mg tablet size is designed for accurate dosing of cats, with a two-way break for administering 0.625mg to smaller cats. Each box contains 100 tablets in blister packs.
Ceva says these features should make it easier for pet owners to be compliant with the recommended treatment protocol and ensure that each cat is getting the right dose, reducing the risk of side-effects.
Amodip will be supported by videos and literature on how to measure hypertension in practice easily and with less stress, written by the International Society of Feline Medicine (ISFM).
For further information or to request copies of the ISFM hypertension materials, contact your local Ceva Animal Health territory manager or call 01494 781510.